Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,259,231 papers from all fields of science
Search
Sign In
Create Free Account
Evaluable Disease
Known as:
Evaluable
Disease that cannot be measured directly by the size of the tumor but can be evaluated by other methods specific to a particular clinical trial.
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
D. Le
,
J. Durham
,
+43 authors
L. Diaz
Science
2017
Corpus ID: 206661248
Predicting responses to immunotherapy Colon cancers with loss-of-function mutations in the mismatch repair (MMR) pathway have…
Expand
Review
2008
Review
2008
Treating Tobacco Use and Dependence: 2008 Update
Tobacco Use and Dependence Guideline Panel
2008
Corpus ID: 68296708
s obtained Abstracts reviewed for inclusion/exclusion criteria by literature reviewerss reviewed for inclusion/exclusion criteria…
Expand
Highly Cited
2006
Highly Cited
2006
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.
S. Nissen
,
S. Nicholls
,
+13 authors
E. Tuzcu
JAMA
2006
Corpus ID: 7629693
Highly Cited
2003
Highly Cited
2003
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
M. Fukuoka
,
S. Yano
,
+17 authors
J. Baselga
Journal of Clinical Oncology
2003
Corpus ID: 7683832
PURPOSE To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839]; AstraZeneca, Wilmington, DE), a…
Expand
Highly Cited
2002
Highly Cited
2002
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial
M. Bolla
,
L. Collette
,
+13 authors
M. Piérart
The Lancet
2002
Corpus ID: 43045963
Highly Cited
2001
Highly Cited
2001
Delirium in mechanically ventilated patients: validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU).
E. Ely
,
S. Inouye
,
+9 authors
R. Dittus
JAMA
2001
Corpus ID: 10828766
CONTEXT Delirium is a common problem in the intensive care unit (ICU). Accurate diagnosis is limited by the difficulty of…
Expand
Highly Cited
2000
Highly Cited
2000
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
J. Douillard
,
D. Cunningham
,
+10 authors
P. Rougier
The Lancet
2000
Corpus ID: 41093096
Highly Cited
2000
Highly Cited
2000
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
F. Shepherd
,
J. Dancey
,
+10 authors
J. Bérille
Journal of Clinical Oncology
2000
Corpus ID: 9795842
PURPOSE To evaluate whether treatment with single-agent docetaxel would result in longer survival than would best supportive care…
Expand
Highly Cited
1999
Highly Cited
1999
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation…
B. Ettinger
,
D. Black
,
+15 authors
S. Cummings
JAMA
1999
Corpus ID: 12191884
CONTEXT Raloxifene hydrochloride, a selective estrogen receptor modulator, prevents bone loss in postmenopausal women, but…
Expand
Highly Cited
1987
Highly Cited
1987
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.
S. Rosenberg
,
M. Lotze
,
+7 authors
J. Rubin
New England Journal of Medicine
1987
Corpus ID: 21523851
We studied the effects of adoptive immunotherapy with lymphokine-activated killer (LAK) cells plus interleukin-2 or therapy with…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE